Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE) two randomised, double-masked, phase 3 trials /

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE) two randomised, double-masked, phase 3 trials /

Saved in:
Bibliographic Details
Main Authors: Wykoff Charles C.
Abreu Francis
Adamis Anthony P.
Basu Karen
Eichenbaum David A.
Haskova Zdenka
Lin Hugh
Loewenstein Anat
Mohan Shaun
Pearce Ian A.
Sakamoto Taiji
Schlottmann Patricio G.
Papp András
Tóth-Molnár Edit
Kollaborációs szervezet: YOSEMITE and RHINE Investigators
Format: Article
Published: 2022
Series:LANCET 399 No. 10326
Subjects:
Szemészet
doi:10.1016/S0140-6736(22)00018-6

mtmt:32673645
Online Access:http://publicatio.bibl.u-szeged.hu/24213
Description
Physical Description:741-755
ISSN:0140-6736

Similar Items